For those with comorbid type 2 diabetes, metformin remains the first-line pharmacologic therapy, improving insulin sensitivity and glycemic control, while GLP-1 receptor agonists are approved for children aged ≥ 10 years. Here, INS is linked to type 2 diabetes mellitus.